Marksans Pharma Ltd. announced its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company’s Board of Directors approved these results and recommended a final dividend of ₹0.90 per equity share (90%). The financial statements were audited by MSKA & Associates LLP, who issued an unmodified opinion. The results are available on the company’s website and stock exchange platforms.
Marksans Pharma Reports FY26 Financials, Recommends Dividend
Marksans Pharma Ltd. has officially released its audited standalone and consolidated financial results for the fiscal year that concluded on March 31, 2026. The Board of Directors, at their meeting held on May 26, 2026, approved these financial statements, which include the audited financial results for the quarter and the full year ended March 31, 2026.
Key Financial Highlights
The company’s standalone revenue from operations for the year ended March 31, 2026, stood at ₹13,414.76 million, a notable increase from the previous year. Profit Before Tax (PBT) was reported at ₹3,915.43 million, and Profit After Tax (PAT) was ₹3,006.98 million. The audited standalone financial results were prepared in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and received an unmodified opinion from the statutory auditors, MSKA & Associates LLP.
Dividend Recommendation
In a significant announcement for shareholders, the Board of Directors has recommended a final dividend of ₹0.90 per equity share, equivalent to 90% of the face value of ₹1 each, for the Financial Year 2025-26. This dividend, if approved by the members at the upcoming Annual General Meeting (AGM), will be credited or dispatched within 30 days from the AGM date.
Consolidated Performance
On a consolidated basis, Marksans Pharma reported revenue from operations of ₹29,509.38 million for the year ended March 31, 2026. The consolidated Profit Before Tax (PBT) was ₹6,239.47 million, and the consolidated Profit After Tax (PAT) was ₹5,605.55 million. The company’s consolidated financial results also received an unmodified opinion from the auditors.
Information Availability
The detailed financial results, along with the auditor’s reports, are now accessible on the company’s official website at www.marksanspharma.com. Investors and stakeholders can also find this information on the websites of the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
Board Meeting Details
The Board meeting where these results were approved commenced at 11:55 AM and concluded at 12:45 PM on May 26, 2026.
Source: BSE
